Do antipsychotics increase diabetes risk in children and adolescents?

Expert Opinion on Drug Safety

Volumn 14, Issue 2, 2015, Pages 219-241

  Galling, Britta ^a   Correll, Christoph U ^a,b,c  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^c FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

Adolescents; Antipsychotics; Children; Diabetes; Glucose; Healthy controls; Hemoglobin a1c; Incidence; Insulin; Psychiatric controls

Indexed keywords

ARIPIPRAZOLE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADOLESCENT; CHILD; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HIGH RISK POPULATION; HUMAN; INCIDENCE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; AGE; BLOOD; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; RISK FACTOR;

ADOLESCENT; AGE FACTORS; ANTIPSYCHOTIC AGENTS; BLOOD GLUCOSE; CHILD; DIABETES MELLITUS, TYPE 2; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; INSULIN RESISTANCE; RISK FACTORS;

EID: 84921395796     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2015.979150     Document Type: Review

References (72)

1. Cooper WO, Arbogast PG, Ding H, et al. Trends in prescribing of antipsychotic medications for US children. Ambul Pediatr Off J Ambul Pediatr Assoc 2006;6(2):79-83
2. Crystal S, Olfson M, Huang C, et al. Broadened use of atypical antipsychotics: safety, effectiveness, and policy challenges. Health Aff Proj Hope 2009;28(5):w770-81
3. Olfson M, Blanco C, Liu L, et al. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry 2006;63(6):679-85
4. Olfson M, Blanco C, Liu SM, et al. National trends in the office-based treatment of children, adolescents, and adults with antipsychotics. Arch Gen Psychiatry 2012;69(12):1247-56
5. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004;161(3):414-25
6. Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013;382(9896):951-62
7. Correll CU. Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents. J Clin Psychiatry 2008;69(Suppl 4):26-36
8. Lambert BL, Cunningham FE, Miller DR, et al. Diabetes risk associated with use of olanzapine, quetiapine, and risperidone in veterans health administration patients with schizophrenia. Am J Epidemiol 2006;164(7):672-81
9. Leucht S, Komossa K, Rummel-Kluge C, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 2009;166(2):152-63
10. Rummel-Kluge C, Komossa K, Schwarz S, et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res 2010;123(2-3):225-33
11. Yood MU, DeLorenze G, Quesenberry CP Jr, et al. The incidence of diabetes in atypical antipsychotic users differs according to agent-results from a multisite epidemiologic study. Pharmacoepidemiol Drug Saf 2009;18(9):791-9
12. Correll CU. Safety and tolerability of antipsychotic treatment in young patients with schizophrenia. J Clin Psychiatry 2011;72(8):e26
13. De Hert M, Dobbelaere M, Sheridan EM, et al. Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: a systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur Psychiatry J Assoc Eur Psychiatr 2011;26(3):144-58
14. De Hert M, Detraux J, van Winkel R, et al. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 2012;8(2):114-26.
15. Maayan L, Correll CU. Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol 2011;21(6):517-35
16. Smith M, Hopkins D, Peveler RC, et al. First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. Br J Psychiatry J Ment Sci 2008;192(6):406-11
17. Correll CU, Manu P, Olshanskiy V, et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA J Am Med Assoc 2009;302(16):1765-73.
18. Correll CU, Kane JM, Manu P. Obesity and coronary risk in patients treated with second-generation antipsychotics. Eur Arch Psychiatry Clin Neurosci 2011;261(6):417-23
19. Foley DL, Mackinnon A, Morgan VA, et al. Predictors of type 2 diabetes in a nationally representative sample of adults with psychosis. World Psychiatry Off J World Psychiatr Assoc WPA 2014;13(2):176-83
20. Nielsen J, Skadhede S, Correll CU. Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol 2010;35(9):1997-2004.
21. Farwell WR, Stump TE, Wang J, et al. Weight gain and new onset diabetes associated with olanzapine and risperidone. J Gen Intern Med 2004;19(12):1200-5
22. Gianfrancesco FD, Grogg AL, Mahmoud RA, et al. Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. J Clin Psychiatry 2002;63(10):920-30
23. Kessing LV, Thomsen AF, Mogensen UB, Andersen PK. Treatment with antipsychotics and the risk of diabetes in clinical practice. Br J Psychiatry J Ment Sci 2010;197(4):266-71
24. Eapen V, John G. Weight gain and metabolic syndrome among young patients on antipsychotic medication: what do we know and where do we go? Australas Psychiatry Bull R Aust N Z Coll Psychiatr 2011;19(3):232-5
25. Fraguas D, Correll CU, Merchán-Naranjo J, et al. Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol 2011;21(8):621-45
26. Kryzhanovskaya LA, Xu W, Millen BA, et al. Comparison of Long-Term (At Least 24 Weeks) Weight Gain and Metabolic Changes Between Adolescents and Adults Treated with Olanzapine. J Child Adolesc Psychopharmacol 2012;22(2):157-65
27. Pringsheim T, Lam D, Ching H, Patten S. Metabolic and neurological complications of second-generation antipsychotic use in children: a systematic review and meta-analysis of randomized controlled trials. Drug Saf Int J Med Toxicol Drug Exp 2011;34(8):651-68
28. Panagiotopoulos C, Ronsley R, Kuzeljevic B, Davidson J. Waist circumference is a sensitive screening tool for assessment of metabolic syndrome risk in children treated with secondgeneration antipsychotics. Can J Psychiatry Rev Can Psychiatr 2012;57(1):34-44
29. Correll CU, Lencz T, Malhotra AK. Antipsychotic drugs and obesity. Trends Mol Med 2011;17(2):97-107
30. Foley DL, Morley KI. Systematic review of early cardiometabolic outcomes of the first treated episode of psychosis. Arch Gen Psychiatry 2011;68(6):609-16
31. Andrade SE, Lo JC, Roblin D, et al. Antipsychotic Medication Use Among Children and Risk of Diabetes Mellitus. Pediatrics 2011;128(6):1135-41.
32. Bobo WV, Cooper WO, Stein CM, et al. Antipsychotics and the Risk of Type 2 Diabetes Mellitus in Children and Youth. JAMA Psychiatry 2013;70(10):1067
33. Correll CU, Kratochvil CJ, March JS. Developments in pediatric psychopharmacology: focus on stimulants, antidepressants, and antipsychotics. J Clin Psychiatry 2011;72(5):655-70
34. Correll CU, Sheridan EM, DelBello MP. Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trials. Bipolar Disord 2010;12(2):116-41
35. Kumra S, Oberstar JV, Sikich L, et al. Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia. Schizophr Bull 2008;34(1):60-71
36. Schimmelmann BG, Schmidt SJ, Carbon M, Correll CU. Treatment of adolescents with early-onset schizophrenia spectrum disorders: in search of a rational, evidence-informed approach. Curr Opin Psychiatry 2013;26(2):219-30
37. Alexander GC, Gallagher SA, Mascola A, et al. Increasing off-label use of antipsychotic medications in the United States, 1995-2008. Pharmacoepidemiol Drug Saf 2011;20(2):177-84
38. Birnbaum ML, Saito E, Gerhard T, et al. Pharmacoepidemiology of antipsychotic use in youth with ADHD: trends and clinical implications. Curr Psychiatry Rep 2013;15(8):382
39. Jensen PS, Youngstrom EA, Steiner H, et al. Consensus report on impulsive aggression as a symptom across diagnostic categories in child psychiatry: implications for medication studies. J Am Acad Child Adolesc Psychiatry 2007;46(3):309-22
40. Zuddas A, Zanni R, Usala T. Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: a review of the randomized controlled studies. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol 2011;21(8):600-20
41. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28(7):412-19
42. Calarge CA, Nicol G, Schlechte JA, Burns TL. Cardiometabolic Outcomes in Children and Adolescents Following Discontinuation of Long-Term Risperidone Treatment. J Child Adolesc Psychopharmacol 2014;24(3):120-9
43. DelBello MP, Versavel M, Ice K, et al. Tolerability of oral ziprasidone in children and adolescents with bipolar mania, schizophrenia, or schizoaffective disorder. J Child Adolesc Psychopharmacol 2008;18(5):491-9
44. Findling RL, Robb A, Nyilas M, et al. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry 2008;165(11):1432-41
45. Findling RL, Nyilas M, Forbes RA, et al. Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2009;70(10):1441-51
46. Fraguas D, Merchán-Naranjo J, Laita P, et al. Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics. J Clin Psychiatry 2008;69(7):1166-75
47. Haas M, Delbello MP, Pandina G, et al. Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study. Bipolar Disord 2009;11(7):687-700
48. Khan RA, Mican LM, Suehs BT. Effects of Olanzapine and Risperidone on Metabolic Factors in Children and Adolescents: a Retrospective Evaluation: J Psychiatr Pract. 2009;15(4):320-8
49. Marcus RN, Owen R, Manos G, et al. Safety and Tolerability of Aripiprazole for irritability in pediatric patients with autistic disorder: a 52-week, open-label, multicenter study. J Clin Psychiatry 2011;72(09):1270-6
50. Margari L, Matera E, Craig F, et al. Tolerability and safety profile of risperidone in a sample of children and adolescents. Int Clin Psychopharmacol 2013;28(4):177-83
51. Ngai YF, Sabatini P, Nguyen D, et al. Quetiapine treatment in youth is associated with decreased insulin secretion. J Clin Psychopharmacol 2014;34(3):359-64
52. Panagiotopoulos C, Ronsley R, Davidson J. Increased prevalence of obesity and glucose intolerance in youth treated with second-generation antipsychotic medications. Can J Psychiatry Rev Can Psychiatr 2009;54(11):743-9
53. Roy G, Bedard A, Desmarais PA, et al. Age-Dependent Metabolic Effects of Second-Generation Antipsychotics in Second-Generation Antipsychotic-Naïve French Canadian Patients. J Child Adolesc Psychopharmacol 2010;20(6):479-87
54. Sikich L, Hamer RM, Bashford RA, et al. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol 2004;29(1):133-45
55. Sikich L, Frazier JA, McClellan J, et al. Double-Blind Comparison of First- and Second-Generation Antipsychotics in Early-Onset Schizophrenia and Schizoaffective Disorder: findings From the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) Study. Am J Psychiatry 2008;165(11):1420-31
56. Swenne I, Rosling A. No unexpected adverse events and biochemical side effects of olanzapine as adjunct treatment in adolescent girls with eating disorders. J Child Adolesc Psychopharmacol 2011;21(3):221-7
57. Weiss M, Panagiotopoulos C, Giles L, et al. A Naturalistic Study of Predictors and Risks of Atypical Antipsychotic Use in an Attention-Deficit/Hyperactivity Disorder Clinic. J Child Adolesc Psychopharmacol 2009;19(5):575-82
58. Enger C, Jones ME, Kryzhanovskaya L, et al. Risk of developing diabetes and dyslipidemia among adolescents with bipolar disorder or schizophrenia. Int J Adolesc Med Health 2013;25(1):3-11
59. McIntyre RS, Jerrell JM. Metabolic and Cardiovascular Adverse Events Associated With Antipsychotic Treatment in Children and Adolescents. Arch Pediatr Adolesc Med 2008;162(10):929
60. Jerrell JM. Adverse events associated with psychotropic treatment in African American children and adolescents. J Natl Med Assoc 2010;102(5):375-83
61. Harrison-Woolrych M, Garcia-Quiroga J, Ashton J, Herbison P. Safety and usage of atypical antipsychotic medicines in children: a nationwide prospective cohort study. Drug Saf Int J Med Toxicol Drug Exp 2007;30(7):569-79
62. Hammerman A, Dreiher J, Klang SH, et al. Antipsychotics and Diabetes: an Age-Related Association. Ann Pharmacother 2008;42(9):1316-22
63. Morrato EH, Nicol GE, Maahs D, et al. Metabolic screening in children receiving antipsychotic drug treatment. Arch Pediatr Adolesc Med 2010;164(4):344-51.
64. Choi BC, Shi F. Risk factors for diabetes mellitus by age and sex: results of the National Population Health Survey. Diabetologia 2001;44(10):1221-31
65. Willett WC, Dietz WH, Colditz GA. Guidelines for healthy weight. N Engl J Med 1999;341(6):427-34
66. Tirosh A, Shai I, Afek A, et al. Adolescent BMI trajectory and risk of diabetes versus coronary disease. N Engl J Med 2011;364(14):1315-25
67. Panagiotopoulos C, Ronsley R, Elbe D, et al. First do no harm: promoting an evidence-based approach to atypical antipsychotic use in children and adolescents. J Can Acad Child Adolesc Psychiatry 2010;19(2):124-37
68. Correll CU. Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes. J Am Acad Child Adolesc Psychiatry 2008;47(1):9-20.
69. Ho J, Panagiotopoulos C, McCrindle B, CAMESA guideline group. Management recommendations for metabolic complications associated with second generation antipsychotic use in children and youth. J Can Acad Child Adolesc Psychiatry 2011;20(3):234-41.
70. Maayan L, Correll CU. Management of antipsychotic-related weight gain. Expert Rev Neurother 2010;10(7):1175-200.
71. Ronsley R, Rayter M, Smith D, et al. Metabolic monitoring training program implementation in the community setting was associated with improved monitoring in second-generation antipsychotic-treated children. Can J Psychiatry Rev Can Psychiatr 2012;57(5):292-9
72. Caemmerer J, Correll CU, Maayan L. Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: a meta-analytic comparison of randomized controlled trials. Schizophr Res 2012;140(1-3):159-68